UNC Childhood, Adolescent, and Young Adult Cancer Cohort
Launched by UNC LINEBERGER COMPREHENSIVE CANCER CENTER · Oct 14, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The UNC Childhood, Adolescent, and Young Adult Cancer Cohort study is looking to gather important information about young people diagnosed with cancer, specifically those under 40 years old at the time of their diagnosis. The goal is to create a registry that helps researchers better understand the long-term effects of cancer treatment on children, teenagers, and young adults. The study focuses particularly on participants aged 15 to 39, who are often referred to as adolescents and young adults (AYAs).
If you or someone you know is between the ages of 0 and 39 and has been diagnosed with cancer, you might be eligible to join the study. Participants will complete various assessments and questionnaires about their health and experiences during and after treatment, and provide samples for research. The study is open to anyone at any point in their cancer journey, whether they are currently in treatment or have completed it. By gathering this data, the researchers hope to gain insights into how cancer and its treatment affect young people's health over time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient ages 0-39 years at the time of cancer diagnosis (ages 1-39 years at enrollment) who are at any point in treatment and survivorship trajectory
- • English or Spanish speaking
- Exclusion Criteria:
- • Unwilling to sign informed consent
- • Speak a language other than English or Spanish.
About Unc Lineberger Comprehensive Cancer Center
The UNC Lineberger Comprehensive Cancer Center is a leading research institution dedicated to advancing cancer treatment and prevention through innovative clinical trials and comprehensive patient care. As a National Cancer Institute-designated comprehensive cancer center, it integrates cutting-edge research, interdisciplinary collaboration, and patient-centered approaches to address diverse oncology challenges. With a commitment to translating scientific discoveries into effective therapies, UNC Lineberger strives to improve outcomes for patients while fostering a robust environment for education and training in cancer research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chapel Hill, North Carolina, United States
Patients applied
Trial Officials
Andrew Smitherman, MD
Principal Investigator
University of North Carolina, Chapel Hill
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials